Seeking Alpha

Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump...

Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump for treating hepatitis C as "a leap forward for viral medicine no less important than the first studies in HIV decades ago." And with the recent failure of a Bristol-Myers treatment in clinical trials, the timing is good. Still, with a number of rival drugs being trialled, one wonders whether di Stefano is guilty of hyperbole.
Comments (3)
  • I wonder why Stephen McMurray, one of Medgenics' directors sold 10,935 shares at $12.50 each on 24 August 2012, without explanation in the news release.
    30 Aug 2012, 04:04 PM Reply Like
  • maybe he just needed some money ? it happens to all of us...
    what is his total holding ?
    3 Sep 2012, 08:18 AM Reply Like
  • there is a mention of it on RNS from 28/8/12
    4 Sep 2012, 04:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)